Form 4: Hims & Hers CEO Andrew Dudum Granted 413,844 RSUs

Hims & Hers Health, Inc. CEO Andrew Dudum was granted 413,844 Restricted Stock Units, vesting over four years starting June 2026.

Summary

• Andrew Dudum, Chief Executive Officer, Director, and 10% Owner of Hims & Hers Health, Inc. (HIMS), was granted 413,844 Restricted Stock Units (RSUs).
• The transaction date for this grant was March 11, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs are subject to a service-based vesting requirement over a 4-year period.
• Vesting will occur in substantially equal quarterly installments on March 15, June 15, September 15, and December 15.
• The first vesting date is scheduled for June 15, 2026.
• Following this transaction, Andrew Dudum beneficially owns 413,844 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily because it strengthens the alignment between the CEO's long-term financial interests and the company's performance, which is generally favorable for shareholders.

Positives

• The grant of Restricted Stock Units to the CEO aligns management's long-term interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The service-based vesting schedule incentivizes the CEO's continued tenure and commitment to the company's strategic objectives over a four-year period.

Negatives

• The RSUs do not have immediate cash value and are subject to a multi-year vesting schedule, meaning the CEO must remain employed for the full period to realize the entire benefit.
• The grant dilutes existing shareholder equity, although the impact from this specific grant is likely minimal.

Risks

• The value of the RSUs is contingent on the future performance of Hims & Hers Health, Inc.'s Class A Common Stock; a decline in stock price would reduce the realized value of the grant.
• The service-based vesting condition means that if the CEO's employment terminates before the vesting dates, unvested RSUs would be forfeited.

Future Outlook

The RSU grant signifies a long-term incentive and retention strategy for the Chief Executive Officer, aligning his financial interests with the company's sustained growth and shareholder value creation over the next four years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to a Chief Executive Officer is a common and widely accepted practice in the healthcare and technology sectors for executive compensation. This method is favored for its ability to align executive incentives with long-term shareholder value, contrasting with pure cash bonuses that may encourage short-term thinking. Companies like Teladoc Health (TDOC) and Amwell (AMWL), also in the telehealth space, frequently utilize similar equity-based compensation structures to retain key talent and motivate performance.

Comparison to Industry Standards

• The four-year service-based vesting schedule is a standard practice in executive compensation across various industries, including technology and healthcare, comparable to grants seen at companies like Amazon (AMZN) or Microsoft (MSFT) for their senior executives.
• The use of RSUs, which convert to common stock upon vesting, is a prevalent form of equity compensation, aligning with practices at peer companies in the digital health sector such as Teladoc Health (TDOC) and GoodRx (GDRX), which also use RSUs to incentivize and retain their leadership.

Related Party Transactions

• Andrew Dudum, as the Chief Executive Officer, Director, and 10% Owner, received a grant of 413,844 Restricted Stock Units from Hims & Hers Health, Inc. on March 11, 2026, which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: The grant of RSUs to the CEO is intended to align his interests with long-term shareholder value creation, potentially leading to more sustained growth strategies. However, it also represents a future dilution of existing shares upon vesting.
• Employees: The CEO's long-term commitment, as signaled by the RSU grant, can contribute to stability and strategic direction, which may positively impact employee morale and retention.

Next Steps

• The RSUs will begin vesting on June 15, 2026, and continue quarterly over the subsequent four years, contingent on Andrew Dudum's continued service to the company.

Key Dates

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Stock Grant, Corporate Governance